Estimating the prevalence of hepatitis C infection in New York City using surveillance data

Epidemiology and Infection

Volumn 142, Issue 2, 2014, Pages 262-269

  Balter, S ^a   Stark, J H ^a   Kennedy, J ^a   Bornschlegel, K ^a   Konty, K ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

Estimating; hepatitis C; prevalence of disease; surveillance

Indexed keywords

RNA;

ADULT; ARTICLE; DEATH; DISEASE SURVEILLANCE; HEALTH CARE PERSONNEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MIGRATION; PREVALENCE; PROBABILITY; RESOURCE ALLOCATION; RNA ANALYSIS; UNITED STATES; EPIDEMIOLOGY; HEALTH SURVEY; YOUNG ADULT;

ADULT; EPIDEMIOLOGIC METHODS; HEPATITIS C; HUMANS; NEW YORK CITY; POPULATION SURVEILLANCE; PREVALENCE; YOUNG ADULT;

EID: 84894292629     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813000952     Document Type: Article

References (36)

1. CDC. Hepatitis C Information for Health Professionals, 2012 (http://www.cdc.gov/hepatitis/HCV/index.htm). Accessed 19 March 2012.
2. Wong T, Lee SS. Hepatitis C: a review for primary care physicians. Canadian Medical Association Journal 2006; 174: 649-659.
3. Ly K N, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine 2012; 156: 271-278.
4. Armstrong GL, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine 2006; 144: 705-714.
5. Bornschlegel K, et al. Prevalence of hepatitis C infection in New York City, 2004. Journal of Urban Health 2009; 86: 909-917.
6. Riley ED, et al. Antiretroviral therapy, hepatitis C virus, and AIDS mortality among San Francisco's homeless and marginally housed. Journal of Acquired Immune Deficiency Syndrome 2005; 38: 191-195.
7. Schwarz KB, et al. Seroprevalence of HCV infection in homeless Baltimore families. Journal Health Carefor the Poor and Underserved 2008; 19: 580-587.
8. Stein JA, Nyamathi A. Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug and Alcohol Dependence 2004; 75: 89-95.
9. Desai RA, Rosenheck RA, Agnello V. Prevalence of hepatitis C virus infection in a sample of homeless veterans. Social Psychiatry and Psychiatric Epidemiology 2003; 38: 396-401.
10. Klinkenberg WD, et al. Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Comparative Psychiatry 2003; 44: 293-302.
11. Cheung RC, et al. Viral hepatitis and other infectious diseases in a homeless population. Journal of Clinical Gastroenterology 2002; 34: 476-480.
12. Fox RK, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clinical Infectious Disease 2005; 41: 177-186.
13. Solomon L, et al. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. Journal of Urban Health 2004; 81: 25-37.
14. Spaulding A, et al. Hepatitis C in state correctional facilities. Preventive Medicine 1999; 28: 92-100.
15. Vlahov D, et al. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. European Journal of Epidemiology 1993; 9: 566-569.
16. Chak E, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver International 2011; 31: 1090-1101.
17. Williams IT, et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Archives of Internal Medicine, 2011; 171: 242-248.
18. Yalamanchili K, et al. The prevalence of hepatitis C virus infection in Texas: implications for future health care. Baylor University Medical Center Proceedings 2005; 18: 3-6.
19. Amon JJ, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clinical Infectious Disease 2008; 46: 1852-1858.
20. Sherman KE, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011; 365: 1014-1024.
21. Lok AS, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. New England Journal of Medicine 2012; 366: 216-224.
22. Maasoumy B, Manns MP. Optimal treatment with boceprevir for chronic HCV infection. Liver International 2013; 33 (Suppl. 1): 14-22.
23. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver International 2013; 33 (Suppl. 1): 93-104.
24. CDC. Signal to cut-off ratios for commercially available assays, 2012 (http://www.cdc.gov/hepatitis/HCV/LabTesting.htm). Accessed 10 May 2012.
25. NYC Department of Health and Mental Hygiene. Hepatitis A, B and C surveillance report (http://www.nyc.gov/html/doh/downloads/pdf/cd/cd-hepabc- surveillance-report-08-09.pdf). Accessed 9 September 2012.
26. Washington, DC: IRS. County to county migration data: 2004-2008. (http://www.irs.gov/uac/SOI-Tax-Stats-County-to-County-Migration-Data-Files). Accessed 22 April 2013.
27. France AM, et al. Estimating the prevalence of chronic hepatitis B virus infection-new york city, 2008. Journal of Urban Health 2012; 89: 373-383.
28. Jauncey M, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. Journal of Infectious Disease 2004; 190: 1270-1274.
29. Colvin HM, Mitchell AE (eds). Hepatitis and Liver Cancer: a National Stratgey for Prevention and Control of Hepatitis B and C. Washington, DC: Institute of Medicine of the National Academies National Academies Press, 2010.
30. Denniston MM, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: NHANES 2001-08. Hepatology 2011; 55: 1652-1661.
31. U.S. Census Bureau. Census 2010 (http://factfinder2. census.gov/legacy/ aff-sunset.html?-lang & en). Accessed 29 November 2011.
32. NYC Hepatitis B and Hepatitis C community site. (http://nychepbc.org/ checkhepc/). Accessed 19 November 2012.
33. U.S. Department of Health & Human Services. The health care law and you (http://www.healthcare. gov/law/index.html) 2012. Accessed 19 November 2012.
34. De Angelis D, et al. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Statistical Methods in Medical Research, 2009; 18: 361-379.
35. Deuffic-Burban S, Mathurin P, Valleron AJ. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Statistical Methods in Medical Research 2009; 18: 233-252.
36. CDC. Surveillance for chronic hepatitis B virus infection-New York City June 2008-November 2009. Morbidity and Mortality Weekly Report 2012; 61: 6-9.